Service de Biochimie Métabolomique et Protéomique, Hôpital Universitaire Necker-Enfants Malades Assistance Publique-Hôpitaux de Paris (AP-HP), France.
PLoS One. 2013;8(3):e59634. doi: 10.1371/journal.pone.0059634. Epub 2013 Mar 25.
The objective of this pharmacodynamic study was to longitudinally assess the activity of calcineurin during the first 2 years after lung transplantation. From March 2004 to October 2008, 107 patients were prospectively enrolled and their follow-up was performed until 2009. Calcineurin activity was measured in peripheral blood mononuclear cells. We report that calcineurin activity was linked to both acute and chronic rejection. An optimal activity for calcineurin with two thresholds was defined, and we found that the risk of rejection was higher when the enzyme activity was above the upper threshold of 102 pmol/mg/min or below the lower threshold of 12 pmol/mg/min. In addition, we report that the occurrence of malignancies and viral infections was significantly higher in patients displaying very low levels of calcineurin activity. Taken together, these findings suggest that the measurement of calcineurin activity may provide useful information for the management of the prevention therapy of patients receiving lung transplantation.
本药效动力学研究的目的是纵向评估肺移植后 2 年内钙调神经磷酸酶的活性。2004 年 3 月至 2008 年 10 月，前瞻性纳入 107 例患者，随访至 2009 年。检测外周血单个核细胞中的钙调神经磷酸酶活性。结果显示钙调神经磷酸酶活性与急性和慢性排斥反应均相关。定义了钙调神经磷酸酶的两个阈值的最佳活性，发现当酶活性高于 102 pmol/mg/min 的上限或低于 12 pmol/mg/min 的下限时，排斥反应的风险更高。此外，我们还发现，钙调神经磷酸酶活性非常低的患者发生恶性肿瘤和病毒感染的风险显著增加。综上所述，这些发现表明钙调神经磷酸酶活性的测量可能为接受肺移植患者的预防治疗管理提供有用的信息。
